The Androgen Receptor T877A Mutant Recruits LXXLL and FXXLF Peptides Differently than Wild-Type Androgen Receptor in a Time-Resolved Fluorescence Resonance Energy Transfer Assay
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The interactions of the ligand binding domain (LBD) of androgen receptor (AR) and the AR T877A mutant, found in prostate cancer, with peptides from coactivator and corepressor proteins or random phage display peptides were investigated using in vitro time-resolved fluorescence resonance energy transfer (TR-FRET). Interaction of wild-type AR LBD with the random phage display peptide D11FxxLF was observed with dihydrotestosterone (DHT), testosterone, R1881, estradiol, spironolactone, progesterone, and cortisol resulting in distinct dose dependency (EC50) values for each ligand and correlating well with the reported rank order potency of these agonists. Increasing concentrations of cyproterone acetate and mifepristone resulted in more complete disruption of the DHT-mediated AR-D11FxxLF peptide interaction, while flutamide, hydroxyflutamide, and bicalutamide caused only partial disruption of the complex. The mutant AR T877A LBD exhibited increased binding affinities for all ligands tested except for bicalutamide, mifepristone, DHT, and R1881 in a competitive binding assay as compared to wild-type AR LBD. This mutation was also characterized by increased ligand potency for agonist-induced peptide recruitment. Although usually an antagonist, hydroxyflutamide was more potent in the recruitment of D11FxxLF or an SRC3-1 LXXLL motif to AR T877A LBD than AR LBD. The antagonist cyproterone acetate behaved as a full antagonist of D11FxxLF recruitment to AR LBD and AR T877A LBD but as a more potent agonist in the recruitment of SRC3-1 to AR T877A LBD. These results suggest that the AR T877A mutation affects both ligand affinity and ligand dose dependency for peptide recruitment and may explain in part the altered responses of antagonists and increased transcriptional activation reported in androgen-independent prostate cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Principles and Biophysical Applications of Lanthanide-Based Probes
Selvin, P. R. (2002) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.31.101101.140927 · Cited by 549
Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N., & Balk, S. P. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.7.0870 · Cited by 121
Cited by
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
“…(18F-FDHT), to measure relative AR binding affinity (Tran et al., 2009), showed that enzalutamide binds with higher affinity to AR F876L than wild-type AR (Figure 2—figure supplement 3), similar to what has been shown for hydroxyflutamide and the AR T877A mutant (Ozers et al., 2007).”
BackgroundThe role of androgen receptor mutations in prostate cancer progression.
Brooke, G., & Bevan, C. (2009) · Current Genomics · doi:10.2174/138920209787581307 · Cited by 181
“Unlike the other steroid receptors, the AR can also interact with and has higher affinity for phenylalanine rich motifs, for example the FQNLF motif found in the N-terminus of the AR and those found in some coactivators, for example Androgen Receptor Activator 70 (ARA70) [46, 47].”
BackgroundAndrogen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Ronacher, K., Hadley, K., Avenant, C., Stubsrud, E., Simons, S. S., Louw, A., & Hapgood, J. P. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.008 · Cited by 121
Brooke, G. N., Parker, M. G., & Bevan, C. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210955 · Cited by 79
“A similar trend was reported for AR T877A by Ozers et al. who showed, using fluorescence resonance energy transfer, that cyproterone acetate antagonized its interaction with an FxxLF-containing peptide, whilst promoting its interaction with an LxxLL-containing peptide (Ozers et al., 2007).”
Metadata
- Authors
- Ozers, M. S., Marks, B. D., Gowda, K., Kupcho, K. R., Ervin, K. M., De Rosier, T., Qadir, N., Eliason, H. C., Riddle, S. M., & Shekhani, M. S.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-12-22
- Volume
- 46
- Issue
- 3
- Pages
- 683-695
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2027398944
- Cited by
- 59
- References
- 5
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.